Stephens Inc. AR Sells 28,925 Shares of Bioventus Inc. (NYSE:BVS)

Stephens Inc. AR decreased its stake in Bioventus Inc. (NYSE:BVS) by 51.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,775 shares of the company’s stock after selling 28,925 shares during the period. Stephens Inc. AR’s holdings in Bioventus were worth $281,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC bought a new position in shares of Bioventus in the 3rd quarter valued at $42,000. Quest Partners LLC acquired a new position in Bioventus in the 3rd quarter worth about $51,000. Quarry LP bought a new position in Bioventus in the third quarter valued at about $59,000. Covestor Ltd acquired a new stake in shares of Bioventus during the third quarter valued at about $69,000. Finally, CWM LLC acquired a new stake in shares of Bioventus during the third quarter valued at about $89,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group upped their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Bioventus Trading Down 0.1 %

NYSE BVS opened at $10.41 on Monday. The firm has a market capitalization of $844.82 million, a PE ratio of -17.07 and a beta of 0.85. The business’s 50-day moving average price is $10.43 and its two-hundred day moving average price is $10.78. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38.

Insider Activity at Bioventus

In related news, CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $113,018.49. Following the transaction, the chief financial officer now owns 105,162 shares in the company, valued at $1,107,355.86. The trade was a 9.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares in the company, valued at $591,172.40. This trade represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,054 shares of company stock worth $401,665 over the last ninety days. Insiders own 32.90% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.